Who are Raltegravir and Abacavir/Lamivudine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Switch to B/F/TAF, Regimen：BIC+FTC+TAF, ELV/COBI/FTC/TAF, DTG/3TC/ABC + ELV/COBI/FTC/TAF, bictegravir/emtricitabine/tenofovir alafenamide, Genvoya Crushed Dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/raltegravir-and-abacavir-lamivudine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Raltegravir and Abacavir/Lamivudine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Raltegravir and Abacavir/Lamivudine (Raltegravir and Abacavir/Lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (INSTI + NRTI) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Raltegravir and Abacavir/Lamivudine (Raltegravir and Abacavir/Lamivudine) — Denver Infectious Disease Consultants, PLLC. This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (abacavir/lamivudine) at different stages of the viral lifecycle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Raltegravir and Abacavir/Lamivudine TARGET	Raltegravir and Abacavir/Lamivudine	Denver Infectious Disease Consultants, PLLC	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Regimen：BIC+FTC+TAF	Regimen：BIC+FTC+TAF	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Genvoya Crushed Dose	Genvoya Crushed Dose	Johns Hopkins University	marketed	Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTI) class)

ViiV Healthcare · 2 drugs in this class
Denver Infectious Disease Consultants, PLLC · 1 drug in this class
Fundacion SEIMC-GESIDA · 1 drug in this class
Fundação Bahiana de Infectologia · 1 drug in this class
Charlotte-Paige Rolle, MD · 1 drug in this class
Saint Michael's Medical Center · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
Hospitales Universitarios Virgen del Rocío · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Raltegravir and Abacavir/Lamivudine — Competitive Intelligence Brief. https://druglandscape.com/ci/raltegravir-and-abacavir-lamivudine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab